Phase 2 HCC Clinical Trials
69 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–20 of 69 trials
Recruiting
Phase 2
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
Hepatocellular CarcinomaHCC
University of California, Irvine35 enrolled1 locationNCT04472767
Recruiting
Phase 2
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
HCC - Hepatocellular CarcinomaConversion Therapy
Tianjin Medical University Cancer Institute and Hospital43 enrolled1 locationNCT07560488
Recruiting
Phase 2
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
Hepato Cellular Carcinoma (HCC)Hand Foot Skin Syndrome
National Taiwan University Hospital39 enrolled1 locationNCT07560566
Recruiting
Phase 2
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
Hepatocellular Carcinoma (HCC)
Second Affiliated Hospital, School of Medicine, Zhejiang University36 enrolled1 locationNCT07422753
Recruiting
Phase 2
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
Hepatocellular Carcinoma (HCC)
Fudan University164 enrolled1 locationNCT06860490
Recruiting
Phase 2
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
Hepato Cellular Carcinoma (HCC)
Fudan University350 enrolled1 locationNCT07328009
Recruiting
Phase 2
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
HCC - Hepatocellular Carcinoma
TaiRx, Inc.40 enrolled1 locationNCT07521852
Recruiting
Phase 2
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
Hepato Cellular Carcinoma (HCC)
Fudan University40 enrolled1 locationNCT07536789
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb129 enrolled46 locationsNCT07291076
Recruiting
Phase 2Phase 3
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Hepatocellular Carcinoma (HCC)
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.680 enrolled2 locationsNCT07490262
Recruiting
Phase 1Phase 2
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Hepatocellular Carcinoma (HCC)
RayzeBio, Inc.590 enrolled13 locationsNCT06726161
Recruiting
Phase 2Phase 3
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
Hepatocellular Carcinoma (HCC)
Tuen Mun Hospital106 enrolled1 locationNCT07293468
Recruiting
Phase 2
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Hepatocellular Carcinoma (HCC)
Ruijin Hospital35 enrolled4 locationsNCT07331883
Recruiting
Phase 2
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University76 enrolled1 locationNCT06737913
Recruiting
Phase 1Phase 2
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Metastatic Liver CancerAdvanced Hepatocellular Carcinoma (HCC)
Beijing Biotech30 enrolled1 locationNCT07500220
Recruiting
Phase 1Phase 2
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
Hepatocellular Carcinoma (HCC)
Yinghua Xu20 enrolled1 locationNCT07495215
Recruiting
Phase 2
Phase 2 Study of WGI-0301 for Advanced HCC
Advanced Hepatocellular Carcinoma (HCC)
Zhejiang Haichang Biotech Co., Ltd.60 enrolled4 locationsNCT06309485
Recruiting
Phase 2
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Hepatocellular Carcinoma (HCC)
Akeso100 enrolled1 locationNCT07052253
Recruiting
Phase 2
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
HCC
Chinese University of Hong Kong40 enrolled2 locationsNCT06823375
Recruiting
Phase 2Phase 3
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
Hepato Cellular Carcinoma (HCC)
University Hospital, Basel, Switzerland152 enrolled3 locationsNCT07302919